Inventiva has extended its cash runway into late Q1 2027 after completing a U.S. public offering in November that raised approximately €149 million in gross proceeds. As of September 30, 2025, the company reported €97.6 million in cash and cash equivalents and €24.7 million in short-term deposits, alongside €4.5 million in revenues for the first nine months of 2025. Financing inflows this year included the settlement of a second tranche of structured financing in May, bringing gross proceeds of €115.6 million, and the recent 44.8 million ADS raise. With potential additional proceeds of up to €116 million from warrant exercises, the runway could stretch to mid-Q3 2027, comfortably past the expected H2 2026 topline readout of the NATiV3 Phase 3 trial of lanifibranor in MASH.
The strategic subtext is clear: this is a bridge-to-data financing designed to carry lanifibranor to a pivotal inflection point without forced partnering or emergency capital. Operating cash burn rose 20% year over year to €76.3 million despite an 11% reduction in R&D expenses, reflecting working capital dynamics and pipeline prioritization. On the top line, a $10 million milestone and $5 million in credit notes recognized under the China partnership with CTTQ provided rare revenue in a space where most players remain pre-commercial. This combination of structured capital, equity markets, and regional licensing underlines how late-stage hepatology programs are being kept solvent in a capital-selective environment.
Why this matters now is the changing calculus in MASH following the first U.S. approval in the category and intensifying payer scrutiny. Should lanifibranor deliver positive Phase 3 data, it would emerge as a potential follow-on oral option with a differentiated pan-PPAR mechanism that could appeal to hepatologists and endocrinologists managing fibrotic liver disease in a metabolic context. For patients, an additional oral therapy could expand access and choice; for payers, the bar will rest on histologic benefit, cardiovascular and renal safety, and real-world adherence in primary and specialty care settings. Medical Affairs teams will need to shape a noninvasive monitoring narrative that aligns with biopsy-light practice patterns, while generating real-world evidence to support step edits, combination use, and long-term outcomes.
For competitors, the financing runway signals that Inventiva intends to stay independent at least through key data. The timing puts NATiV3 readout squarely into a period when treatment algorithms, coverage policies, and diagnostic pathways are evolving, creating an opening for mechanism-based differentiation on fibrosis improvement, metabolic parameters, and tolerability. It also raises the prospect of rational combinations, given the rapid expansion of GLP-1s and the appetite for multi-pathway strategies in metabolic liver disease, though safety interactions and payer willingness to reimburse combinations will be decisive.
The broader trend is European biotechs tapping U.S. capital and hybrid structures to survive to value-creating catalysts, particularly in high-burden chronic diseases where commercial infrastructure and payer engagement are complex. For BD teams, the message is to prepare for a competitive 2026–2027 deal window in MASH, with regional rights, co-promotion constructs, and post-approval RWE commitments as potential levers. The critical question is whether lanifibranor’s Phase 3 profile can clear the clinical and economic thresholds that payers and guideline bodies are rapidly setting in the post-first-approval era—and whether Inventiva moves first to lock in a commercial partner ahead of readout or waits to maximize leverage once the data arrives.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
